Benefits of Trimetazidine in MASLD Patients

Evaluation of Potential Benefits of Trimetazidine in the Management of Patients With Metabolic Associated Steatotic Liver Disease (MASLD)

Objective of this study is to determine the clinical benefits of trimetazidine in improvement of MASLD

the study will evaluate the possible benefits of trimetazidine when added to pateints with metabolic associated fatty liver disease

Inclusion Criteria: participants were included if they met MASLD diagnostic criteria, which required imaging-confirmed hepatic steatosis (via abdominal ultrasound and CAP), along with metabolic factors (BMI ≥25 kg/m², diabetes/dysglycemia, blood pressure ≥130/85 mmHg, triglycerides ≥150 mg/dL, or reduced HDL-cholesterol)

Exclusion Criteria: The study excluded those with

• alternative steatosis causes (alcohol intake >50 g/day women or >60 g/day men
• drug-induced injury, hepatitis C, Wilson disease).
• Additional exclusion criteria covered ages below 18 years, pregnancy. decompensated cirrhosis, portal hypertension, hepatocellular carcinomas.
• Trimetazidine contraindications (Parkinson's disease, parkinsonian symptoms, tremors, severe renal impairment), patients on statins, sodium glucose transporter 2 inhibitors (SGLT2), glucagon-like peptide 1(GLP1) were among the other exclusion criteria